- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California
Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it has entered into an exclusive license agreement with The Regents of the University of California. As quoted in the press release: Under the agreement, the Company has …
Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it has entered into an exclusive license agreement with The Regents of the University of California.
As quoted in the press release:
Under the agreement, the Company has exclusive rights in all fields of use for a patent family that claims a method of improving recovery in a patient that has suffered an ischemic stroke by administering to the patient stem cell-derived oligodendrocyte progenitor cells. The pending patent applications in the US, Canada, China, Japan, Australia, and before the European Patent Organization that are included in the exclusive license were filed after initial testing of AST-OPC1, the Company’s pluripotent stem cell derived oligodendrocyte progenitor cell product, in a rodent model of white matter ischemia in collaboration with Dr. S. Thomas Carmichael, M.D., Ph.D., Chair and Professor of Neurology at the University of California, Los Angeles (“UCLA”).  The pending patents are jointly owned by The Regents of The University of California and Asterias, with The Regents granting the Company an exclusive license to its share of the IP rights.
The exclusive license agreement with the Regents of the University of California is a part of the Company’s strategy to explore the efficacy of its AST-OPC1 product candidate in other neurological conditions. AST-OPC1 is currently in a Phase 1/2a clinical trial in severe spinal cord injury (NCT02302157).
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â